Ongoing Clinical Trials
Cardiovascular Outcomes Trial
AN INVITATION TO THE
SYNCHRONIZE CVOT STUDY
Investigative Incretin -3.6mg/6.0mg/placebo
High Risk for CVD, or have CKD
with or without Type 2 Diabetes
Type 1 Diabetes Renal Protection
FINE-ONE CLINICAL STUDY
Finerenone -10mg/20mg/placebo
CKD in Type 1 Diabetes
adtekron@ucalgary.ca
SUGARNSALT Trial
Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial
The purpose of this study is to find out if a drug called sotagliflozin (SOTA) can slow kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease (defined as greater than 50% reduction in kidney filtering function and the leakage of increased amounts of protein in the urine).
The study will enroll 150 participants and last 3.5 years. Participants will have:
- Type 1 Diabetes with moderate kidney dysfunction
- Must be willing to monitor blood glucose and ketones throughout the study
Eli Lilly - Incretin Study
AN INVITATION TO THE
TRANSCEND-T2D-2 CLINICAL STUDY
Retatrutide vs Semaglutide
Type 2 Diabetes
victoria.tully@ucalgary.ca
Bookmark our Website!
Our research participants travel to us from Calgary and the surrounding area. Please reach out, as we will work with you to support rural participation in our trials.
We are open for important research that provides medical care to patients living with chronic diseases.
Please come back to this website as we will continue to update our active clinical trials page!